Page 46 - IMO-2-3

Innovative Medicines & Omics Tyrosine kinases: Structure, mechanism, and therapeutics

doi: 10.5306/wjco.v2.i2.80 evaluation of CO-1686, an irreversible, highly selective
tyrosine kinase inhibitor of mutations of EGFR (activating
130. Agrawal M, Garg RJ, Cortes J, Quintás-Cardama A. Tyrosine and T790M). J Clin Oncol. 2014;32(15_suppl):8010.
kinase inhibitors: The first decade. Curr Hematol Malig
Rep. 2010;5(2):70-80. doi: 10.1200/jco.2014.32.15_suppl.8010
doi: 10.1007/s11899-010-0045-y 140. Jiang T, Zhou C. Clinical activity of the mutant-selective
EGFR inhibitor AZD9291 in patients with EGFR inhibitor-
131. Yang JC, Shih JY, Su WC, et al. Afatinib for patients with resistant non-small cell lung cancer. Transl Lung Cancer Res.
lung adenocarcinoma and epidermal growth factor receptor 2014;3(6):370-372.
mutations (LUX-Lung 2): A phase 2 trial. Lancet Oncol.
2012;13(5):539-548. doi: 10.3978/j.issn.2218-6751.2014.08.02
doi: 10.1016/s1470-2045(12)70086-4 141. Kim D-W, Lee DH, Kang JH, et al. Clinical activity and
safety of HM61713, an EGFR-mutant selective inhibitor,
132. Sequist LV, Besse B, Lynch TJ, et al. Neratinib, an irreversible in advanced non-small cell lung cancer (NSCLC) patients
pan-ErbB receptor tyrosine kinase inhibitor: Results of a (pts) with EGFR mutations who had received EGFR
phase II trial in patients with advanced non-small-cell lung tyrosine kinase inhibitors (TKIs). J Clin Oncol. 2014;32(15_
cancer. J Clin Oncol. 2010;28(18):3076-3083.
suppl):8011.
doi: 10.1200/jco.2009.27.9414
doi: 10.1200/jco.2014.32.15_suppl.8011
133. Pietanza MC, Lynch TJ Jr., Lara PN Jr., et al. XL647--a 142. Janjigian YY, Azzoli CG, Krug LM, et al. Phase I/II
multitargeted tyrosine kinase inhibitor: Results of a phase trial of cetuximab and erlotinib in patients with lung
II study in subjects with non-small cell lung cancer who adenocarcinoma and acquired resistance to erlotinib. Clin
have progressed after responding to treatment with either Cancer Res. 2011;17(8):2521-2527.
gefitinib or erlotinib. J Thorac Oncol. 2012;7(1):219-226.
doi: 10.1158/1078-0432.Ccr-10-2662
doi: 10.1097/JTO.0b013e31822eebf9
143. Janjigian YY, Smit EF, Groen HJ, et al. Dual inhibition of
134. Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo EGFR with afatinib and cetuximab in kinase inhibitor-
for patients with advanced, metastatic non-small-cell lung resistant EGFR-mutant lung cancer with and without
cancer after failure of erlotinib, gefitinib, or both, and one T790M mutations. Cancer Discov. 2014;4(9):1036-1045.
or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3
randomised trial. Lancet Oncol. 2012;13(5):528-538. doi: 10.1158/2159-8290.Cd-14-0326
doi: 10.1016/s1470-2045(12)70087-6 144. Goldberg SB, Oxnard GR, Digumarthy S, et al. Chemotherapy
with Erlotinib or chemotherapy alone in advanced non-small
135. Katakami N, Atagi S, Goto K, et al. LUX-Lung 4: A phase II cell lung cancer with acquired resistance to EGFR tyrosine
trial of afatinib in patients with advanced non-small-cell lung kinase inhibitors. Oncologist. 2013;18(11):1214-1220.
cancer who progressed during prior treatment with erlotinib,
gefitinib, or both. J Clin Oncol. 2013;31(27):3335-3341. doi: 10.1634/theoncologist.2013-0168
doi: 10.1200/jco.2012.45.0981 145. Kelly MP, Nikolaev VO, Gobejishvili L, et al. Cyclic
nucleotide phosphodiesterases as drug targets. Pharmacol
136. Reckamp KL, Giaccone G, Camidge DR, et al. A phase 2 trial Rev. 2025;77(3):100042.
of dacomitinib (PF-00299804), an oral, irreversible pan-
HER (human epidermal growth factor receptor) inhibitor, doi: 10.1016/j.pharmr.2025.100042
in patients with advanced non-small cell lung cancer 146. Roskoski R. Properties of FDA-approved small molecule
after failure of prior chemotherapy and erlotinib. Cancer. protein kinase inhibitors: A 2024 update. Pharmacol Res.
2014;120(8):1145-1154. 2024;200:107059.
doi: 10.1002/cncr.28561 doi: 10.1016/j.phrs.2024.107059
137. Pollak M. Insulin and insulin-like growth factor signalling 147. Fauvel B, Yasri A. Antibodies directed against receptor
in neoplasia. Nat Rev Cancer. 2008;8(12):915-928. tyrosine kinases: Current and future strategies to fight
cancer. MAbs. 2014;6(4):838-851.
doi: 10.1038/nrc2536
doi: 10.4161/mabs.29089
138. Camidge DR, Bazhenova L, Salgia R, et al. First-in-human
dose-finding study of the ALK/EGFR inhibitor AP26113 in 148. Slichenmyer WJ, Fry DW. Anticancer therapy targeting
patients with advanced malignancies: Updated results. J Clin the erbB family of receptor tyrosine kinases. Semin Oncol.
Oncol. 2013;31(15_suppl):8031. 2001;28(5 Suppl 16):67-79.
doi: 10.1200/jco.2013.31.15_suppl.8031 doi: 10.1016/s0093-7754(01)90284-2
139. Sequist LV, Soria JC, Gadgeel SM, et al. First-in-human 149. Ciardiello F, Tortora G. A novel approach in the treatment of

Volume 2 Issue 3 (2025) 40 doi: 10.36922/IMO025200022